Holen Sie sich die Stockscreener-App
26.18
3.36%
0.85
Handel nachbörslich:
25.00
-1.18
-4.51%
Schlusskurs vom Vortag:
$25.33
Offen:
$25.15
24-Stunden-Volumen:
993.56K
Relative Volume:
1.08
Marktkapitalisierung:
$1.30B
Einnahmen:
$290.38M
Nettoeinkommen (Verlust:
$-21.03M
KGV:
-60.97
EPS:
-0.4294
Netto-Cashflow:
$-54.99M
1W Leistung:
+8.14%
1M Leistung:
-4.24%
6M Leistung:
+62.61%
1J Leistung:
-8.37%
1-Tages-Spanne:
$24.81
$26.25
1-Wochen-Bereich:
$23.25
$26.25
52-Wochen-Spanne:
$15.59
$35.87
Staar Surgical Co Stock (STAA) Company Profile
Firmenname
Staar Surgical Co
Sektor
Telefon
(626) 303-7902
Adresse
1911 WALKER AVE, MONROVIA, CA
Compare STAA vs ISRG, BDX, ALC, RMD, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STAA
Staar Surgical Co
|
26.18 | 1.27B | 290.38M | -21.03M | -54.99M | -0.4294 |
ISRG
Intuitive Surgical Inc
|
394.51 | 141.76B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
183.40 | 50.00B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
74.25 | 35.57B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
224.46 | 32.78B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.74 | 31.15B | 29.14B | 1.07B | 1.05B | 1.1956 |
Staar Surgical Co Stock (STAA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2026-02-03 | Eingeleitet | Wedbush | Neutral |
| 2026-01-16 | Fortgesetzt | Morgan Stanley | Underweight |
| 2025-04-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-02-12 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2025-02-12 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-02-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-06-11 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-03-11 | Hochstufung | Stifel | Hold → Buy |
| 2023-12-05 | Herabstufung | Needham | Buy → Hold |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-09-15 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-08-03 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-06-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-04-17 | Eingeleitet | Piper Sandler | Neutral |
| 2023-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-12-28 | Bestätigt | BTIG Research | Buy |
| 2022-12-08 | Eingeleitet | Stifel | Hold |
| 2022-11-07 | Hochstufung | Sidoti | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-28 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2022-03-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-07-09 | Eingeleitet | Oppenheimer | Perform |
| 2021-01-19 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-10-26 | Herabstufung | Sidoti | Buy → Neutral |
| 2020-08-31 | Hochstufung | Sidoti | Neutral → Buy |
| 2020-08-06 | Bestätigt | The Benchmark Company | Buy |
| 2020-07-06 | Herabstufung | Sidoti | Buy → Neutral |
| 2020-06-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-06-15 | Eingeleitet | Jefferies | Buy |
| 2019-12-04 | Eingeleitet | BTIG Research | Buy |
| 2018-09-24 | Bestätigt | The Benchmark Company | Buy |
| 2018-08-06 | Fortgesetzt | The Benchmark Company | Buy |
| 2017-11-20 | Bestätigt | The Benchmark Company | Buy |
| 2017-08-14 | Bestätigt | The Benchmark Company | Buy |
| 2017-03-03 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-18 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2013-09-10 | Fortgesetzt | The Benchmark Company | Buy |
| 2013-02-28 | Bestätigt | The Benchmark Company | Buy |
| 2012-11-01 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2012-03-02 | Eingeleitet | Northland Securities | Outperform |
| 2011-10-25 | Bestätigt | The Benchmark Company | Buy |
| 2010-10-12 | Eingeleitet | Morgan Joseph | Buy |
| 2010-05-11 | Eingeleitet | Benchmark | Buy |
Alle ansehen
Staar Surgical Co Aktie (STAA) Neueste Nachrichten
Why STAAR Surgical (STAA) Is Up 8.1% After Returning To Profit Under New CEO Warren Foust – And What's Next - simplywall.st
STAA Q2 Deep Dive: China Demand and Product Expansion Drive Revenue Growth Amid Market Caution - Yahoo Finance
STAAR Surgical (STAA) Gives Warren Foust The CEO Role After Its Profit Reset - Yahoo Finance
Quantinno Capital Management LP Takes $1.11 Million Position in STAAR Surgical Company $STAA - marketbeat.com
Staar Surgical Co (STAA) Shares Surge 3.4% -- What GF Score of 8 - GuruFocus
STAAR Surgical (STAA) reports 8.4% stake held by Madison Avenue group - Stock Titan
STAAR Surgical earnings beat by $0.02, revenue topped estimates - Investing.com Canada
STAAR Surgical (STAA) Stock Price Shrugs Off Profit Rebound As China Dominates - simplywall.st
Jefferies cuts STAAR Surgical stock price target on estimate update By Investing.com - Investing.com South Africa
STAA Maintains Rating by UBS -- Price Target Lowered to $19.00 - GuruFocus
Jefferies cuts STAAR Surgical stock price target on estimate update - Investing.com
STAA Maintained by Wedbush -- Price Target Lowered to $37.00 - GuruFocus
Piper Sandler reiterates Neutral on STAAR Surgical stock at $33 By Investing.com - Investing.com South Africa
Piper Sandler reiterates Neutral on STAAR Surgical stock at $33 - Investing.com
STAAR Surgical Company Q2 2026 Earnings Call Summary - Yahoo Finance
Staar Surgical Co (STAA) (Q2 2026) Earnings Call Highlights: Record Revenue Surge and Strategic ... - Yahoo Finance
STAA SWOT Analysis: Strong Financial Recovery Revealed in 10-Q F - GuruFocus
STAA Looks 19.9% Undervalued on GF Value™ - GuruFocus
Why STAAR Surgical (STAA) Is Getting Fresh Attention Now - simplywall.st
Earnings call transcript: STAAR Surgical tops revenue views in Q2 2026 - Investing.com Nigeria
STAAR Surgical Q2 EPS $0.16 beats $0.15 estimate; sales up 111% - scanx.trade
STAAR Surgical (NASDAQ:STAA) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS - marketbeat.com
Is Staar Surgical Co (STAA) Undervalued After Q2 Earnings? EPS a - GuruFocus
STAAR Surgical Posts Strong Q2 2026 Earnings, Net Income Surges to $8.1 Million - Kalkine Media
STAAR Surgical Company (STAA) Q2 FY2026 earnings call transcript - Yahoo Finance
STAAR Surgical Q2 2026 Earnings: China Rebound Restores Profitability - TradingKey
Earnings Flash (STAA) STAAR Surgical Posts Q2 EPS $0.16, vs. FactSet Est of $0.14 - marketscreener.com
Staar Surgical: Q2 Earnings Snapshot - marketscreener.com
STAAR Surgical (STAA) more than doubles Q2 sales and returns to profit - Stock Titan
STAAR Surgical Reports Second Quarter 2026 Results - Business Wire
STAAR Surgical faces earnings test amid China growth, CEO transition - Investing.com
STAA|STAAR Surgical Co|Price:26.180|Chg%:+0.850 - TradingKey
Defender Capital LLC. Has $12.37 Million Position in STAAR Surgical Company $STAA - marketbeat.com
Masimo, Staar Name New Leaders - Orange County Business Journal
Renaissance Technologies LLC Acquires 97,400 Shares of STAAR Surgical Company $STAA - marketbeat.com
How Investors Are Reacting To STAAR Surgical (STAA) Formalizing Warren Foust’s CEO Role And Leadership Structure - simplywall.st
Janus Henderson Group PLC Sells 82,283 Shares of STAAR Surgical Company $STAA - marketbeat.com
STAAR Surgical Company $STAA Holdings Raised by Dimensional Fund Advisors LP - marketbeat.com
Staar Surgical Names Warren Foust Permanent CEO, CFO Promoted - The Globe and Mail
STAA Stock On Track For Its Fourth Straight Session Of Gains – This Analyst Would Rather Be Early Than Late On Staar’s Growth Story - Stocktwits
STAAR Surgical Appoints Warren Foust as Permanent CEO with Detailed Compensation Plan - Kalkine Media
Form 8K STAAR Surgical Company For: 6 August By Investing.com - Investing.com Canada
STAAR Surgical (NASDAQ: STAA) names Warren Foust chief executive - Stock Titan
STAAR Surgical appoints Warren Foust as permanent CEO - MedTech Dive
Staar Appoints Warren Foust as Permanent CEO - Orange County Business Journal
STAAR Surgical Names Warren Foust as Permanent CEO - Medical Product Outsourcing
Staar Surgical Appoints Warren Foust as President and CEO - Eyewire+
Warren Foust Named President and CEO of STAAR Surgical, Deborah Andrews Transitions to Executive Vice President and CFO Roles - VisionMonday.com
STAAR Surgical names Warren Foust CEO, Andrews to EVP and CFO - Investing.com
Staar Surgical picks current COO, former J&J exec as new CEO - MassDevice
STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer - marketscreener.com
Finanzdaten der Staar Surgical Co-Aktie (STAA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.90%
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):